Crispr Therapeutics shares tumble after significant earnings miss
Healthpeak Properties, Inc. (NYSE:DOC) Director Scott M. Brinker reported purchasing 1,490 shares of common stock on August 4, 2025. The shares were bought at $16.83, for a total transaction value of $25,076. The purchase comes as the $12 billion healthcare REIT trades near its 52-week low of $16.64, while offering a substantial 7.27% dividend yield. According to InvestingPro analysis, the stock appears undervalued at current levels.
Following the transaction, Brinker directly owns 211,906 shares of Healthpeak Properties. The company has maintained dividend payments for 41 consecutive years, demonstrating strong financial stability. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report about Healthpeak Properties, helping investors make more informed decisions.
In other recent news, Healthpeak Properties reported its second-quarter 2025 earnings, revealing a mixed performance. The company’s earnings per share (EPS) fell short of expectations, coming in at $0.05 compared to the forecasted $0.064, marking a 21.88% shortfall. However, Healthpeak’s revenue slightly exceeded projections, reaching $694.35 million against an anticipated $689.32 million. This earnings announcement was followed by a downgrade from Scotiabank (TSX:BNS), which moved Healthpeak Properties from Sector Outperform to Sector Perform, citing weak leasing performance and increased laboratory credit risk concerns. Additionally, Scotiabank adjusted its price target for the company to $19.00. KeyBanc also maintained its Sector Weight rating on Healthpeak Properties, highlighting ongoing lab occupancy issues affecting the healthcare REIT’s performance. These developments reflect challenges the company faces in the current market environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.